Press Releases
Search
-
14 Dec. 2023
CATTI and bioMérieux Canada are joining forces to support the development of a qualified workforce in advanced therapies
CATTI and bioMérieux Canada are combining their respective strengths to enhance the training of the workforce in advanced therapies and the production of quality control solutions (for the pharmaceutical industries).
-
22 Nov. 2023
bioMérieux Canada, AMMI Canada, EPIC and AMR-One Health Consortium co-host the second Canadian symposium to fight antimicrobial resistance
Declared by the WHO as one of the top ten threats to global public health and identified by Canada's Ministry of Health as one of the greatest concerns of our time, leading players in healthcare and research are mobilizing to combat antimicrobial resistance (AMR).
-
28 Aug. 2023
BIOMÉRIEUX CANADA RECEIVES HEALTH CANADA APPROVAL FOR ITS BIOFIRE® JOINT INFECTION (JI) PANEL
Montréal, Canada – 28-08-2023 – bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® Joint Infection (JI) Panel has received Health Canada Approval. This panel rapidly tests for 31 pathogens commonly associated with joint infections and 8 antimicrobial resistance (AMR) genes, optimizing timely antibiotic therapy and stewardship.
-
01 Feb. 2023
MAESTRIA™, a new generation microbiology middleware developed by bioMérieux to optimize laboratory workflow and improve patient care
Marcy-l’Étoile, France – February 1st, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, launches MAESTRIA™. This new generation middleware for the microbiology laboratory aims at providing a central software tool for the workflow management of all routine activities.
-
12 Apr. 2022
bioMérieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics, an innovative company focusing on fast AST solution
Marcy l’Étoile, France, April 12th 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures. bioMérieux has held a minority stake in Specific Diagnostics since 2019, and the two companies had signed a co-distribution agreement covering the European market in 2021.